TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15134793

Group type: EXPERIMENTAL
Intervention: Snoezelen room
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Vocational skills training
Number of subjects: 15

Group type: COMPARATOR
Intervention: Activities of Daily Living (ADL) skills training
Number of subjects: 15
Study: 11734939

Group type: EXPERIMENTAL
Intervention: Second Look CAD (CADx Medical Systems, Quebec, Canada)
Number of subjects: 150
Study: 9215249

Group type: EXPERIMENTAL
Intervention: Cetirizine (20 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7897254

Group type: EXPERIMENTAL
Intervention: IFN-alpha treatment
Number of subjects: 24
Study: 2888648

Group type: EXPERIMENTAL
Intervention: Oral temazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Papaveretum and hyoscine
Number of subjects: 0
Study: 31339474

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 13483

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg daily
Number of subjects: 13483

Group type: EXPERIMENTAL
Intervention: CKD (eGFR < 60 mL/min/1.73 m2)
Number of subjects: 13483
Study: 28775001

Group type: EXPERIMENTAL
Intervention: Intranasal theophylline
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 161
Study: 26036454

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (8-week randomized controlled trial)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Remitted recurrent MDD patients
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 187
Study: 23770517

Group type: EXPERIMENTAL
Intervention: Cycle training (3 sessions)
Number of subjects: 5
Study: 22104038

Group type: EXPERIMENTAL
Intervention: Cytisine (25-day course of tablets)
Number of subjects: 1310

Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT) (usual care: eight weeks of NRT patch and/or gum or lozenge)
Number of subjects: 1310
Study: 19665037

Group type: EXPERIMENTAL
Intervention: Physical Activity Across the Curriculum (PAAC) intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 17102775

Group type: EXPERIMENTAL
Intervention: tacrolimus+sirolimus
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: tacrolimus+mycophenolate mofetil (MMF)
Number of subjects: 54

Group type: COMPARATOR
Intervention: sirolimus+MMF+daclizumab
Number of subjects: 54
Study: 15650072

Group type: EXPERIMENTAL
Intervention: Fixed orthodontic appliance (FOA)
Number of subjects: 27
Study: 14551293

Group type: EXPERIMENTAL
Intervention: Aggressive cytoreduction with hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic chemotherapy (fluorouracil‐leucovorin)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard treatment consisting of systemic chemotherapy (fluorouracil‐leucovorin) with or without palliative surgery
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: HIPEC group with 0 to 5 regions of the abdominal cavity involved by tumor
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cytoreduction was macroscopically complete (R-1)
Number of subjects: 105
Study: 10085543

Group type: EXPERIMENTAL
Intervention: High event-cue frequency
Number of subjects: 0

Group type: COMPARATOR
Intervention: General knowledge test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prose-reading task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First and final set of event-cues under high event-cue frequency conditions
Number of subjects: 0
Study: 7601919

Group type: EXPERIMENTAL
Intervention: Subgingival application of 2% minocycline ointment administered at baseline, week 2, and months 1, 3, 6, and 9.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Systemic administration of minocycline following scaling/root planing for 10 days.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both subgingival and systemic administration groups.
Number of subjects: 20
Study: 2224377

Group type: EXPERIMENTAL
Intervention: Early operation (surgery completed by follow-up)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (awaiting surgery)
Number of subjects: 40
Study: 352236

Group type: EXPERIMENTAL
Intervention: Madopa
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sinemet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 20
Study: 30972456

Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no rabeprazole)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 14
Study: 27855293

Group type: EXPERIMENTAL
Intervention: Tapered distal tip guidewire (0.010in. or less)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Regular distal tip guidewire (0.014in. size)
Number of subjects: 260
Study: 26523444

Group type: EXPERIMENTAL
Intervention: FOLFOX-A (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 2400 mg/m2, nab-paclitaxel 150 mg/m2 every 2 weeks)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: FOLFOX-A (oxaliplatin 65 mg/m2 if grade 2 neuropathy developed)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: FOLFOX-A (with cumulative neurotoxicity assessment)
Number of subjects: 35
Study: 25091854

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: SIT 30
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: SIT 15
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All groups (ET, SIT 30, SIT 15)
Number of subjects: 36
Study: 21857520

Group type: EXPERIMENTAL
Intervention: Hyperbaric articaine 84 mg (group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 7 mg along with fentanyl 10 μg (group B+F)
Number of subjects: 80
Study: 19150019

Group type: EXPERIMENTAL
Intervention: Lifestyle modification program (dietary modification, physical activity, educational sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal recommendations (control group)
Number of subjects: 0
Study: 17242084

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 20

Group type: COMPARATOR
Intervention: Noninvasive sham acupuncture
Number of subjects: 20
Study: 15069044

Group type: EXPERIMENTAL
Intervention: PEARLS intervention (n = 72)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Usual care (n = 66)
Number of subjects: 138
Study: 12230024

Group type: EXPERIMENTAL
Intervention: Mao-to (8 patients)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dai-seiryu-to (4 patients)
Number of subjects: 28

Group type: COMPARATOR
Intervention: IFN-beta alone (16 patients in group C)
Number of subjects: 28
Study: 9862250

Group type: EXPERIMENTAL
Intervention: Quinapril (lipophilic ACEI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril (hydrophilic ACEI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenylephrine (vasoconstrictor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prostaglandin F2alpha (PGF2alpha)
Number of subjects: 0
Study: 7646751

Group type: EXPERIMENTAL
Intervention: One-month intensive training program in psychosocial medicine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intensive training)
Number of subjects: 26
Study: 29961045

Group type: EXPERIMENTAL
Intervention: Sofu-Net (stepped, collaborative and coordinated health care network)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 218
Study: 26815944

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) in patients with a history of uveitis
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo in patients with a history of uveitis
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) in AS patients
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) in nr-axial SpA patients
Number of subjects: 325
Study: 24996511

Group type: EXPERIMENTAL
Intervention: Culturally sensitive patient information material
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard translated patient information material
Number of subjects: 0
Study: 23880099

Group type: EXPERIMENTAL
Intervention: Low-dose tranexamic acid (10 mg kg(‐1) followed by 1 mg kg(‐1) h(‐1) infusion and 1 mg kg(‐1) into the CPB)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: High-dose tranexamic acid (30 mg kg(‐1) followed by 16 mg kg(‐1) h(‐1) infusion and 2 mg kg(‐1) into the CPB)
Number of subjects: 61
Study: 20626383

Group type: EXPERIMENTAL
Intervention: PEG + Asc
Number of subjects: 107

Group type: COMPARATOR
Intervention: PEG + Bis
Number of subjects: 107
Study: 18853230

Group type: EXPERIMENTAL
Intervention: Inulin-enriched pasta
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control pasta
Number of subjects: 22
Study: 16573869

Group type: EXPERIMENTAL
Intervention: Guards
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prisoners
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tyrannical regime
Number of subjects: 0
Study: 14687273

Group type: EXPERIMENTAL
Intervention: Relative Risk Reduction (RRR)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Absolute Risk Reduction (ARR)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Combination (COMBO)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Numbers Needed to Treat (NNT)
Number of subjects: 357
Study: 10934090

Group type: EXPERIMENTAL
Intervention: Zafirlukast (80 mg twice daily)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study: 8755677

Group type: EXPERIMENTAL
Intervention: Intervention group (received smoking prevention program)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Comparison group (did not receive smoking prevention program)
Number of subjects: 206
Study: 1557595

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3926612

Group type: EXPERIMENTAL
Intervention: Nitroglycerin patches delivering 5 mg/24 hours
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nitroglycerin patches delivering 10 mg/24 hours
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nitroglycerin patches delivering 20 mg/24 hours
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nitroglycerin patches delivering 30 mg/24 hours
Number of subjects: 16
Study: 31988233

Group type: EXPERIMENTAL
Intervention: LEE011 (ribociclib) 400 mg daily for 21 days
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: LEE011 (ribociclib)
Number of subjects: 47
Study: 30485685

Group type: EXPERIMENTAL
Intervention: Parecoxib sodium administered 30 minutes before surgery.
Number of subjects: 88

Group type: COMPARATOR
Intervention: Saline administered 30 minutes before surgery (Control group).
Number of subjects: 88
Study: 26255814

Group type: EXPERIMENTAL
Intervention: Rebound exercise (3 times per week for 20-30 minutes over 9 weeks at moderate intensity of 40-60% of heart rate maximum)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (watched videos and read health magazines)
Number of subjects: 90
Study: 26044763

Group type: EXPERIMENTAL
Intervention: Usual care with additional support delivered by telephone and internet
Number of subjects: 24152

Group type: EXPERIMENTAL
Intervention: Decline forms returned by patients
Number of subjects: 24152

Group type: EXPERIMENTAL
Intervention: Telehealth-related reasons for declining participation
Number of subjects: 24152

Group type: EXPERIMENTAL
Intervention: Health need-related reasons for declining participation
Number of subjects: 24152

Group type: EXPERIMENTAL
Intervention: Life circumstances-related reasons for declining participation
Number of subjects: 24152

Group type: EXPERIMENTAL
Intervention: Research-related reasons for declining participation
Number of subjects: 24152
Study: 23589163

Group type: EXPERIMENTAL
Intervention: PTH(1-84) (100 μg/day) + ibandronate (150 mg/month)
Number of subjects: 43
Study: 21037431

Group type: EXPERIMENTAL
Intervention: Hypothermic machine perfusion
Number of subjects: 164

Group type: COMPARATOR
Intervention: Static cold storage
Number of subjects: 164
Study: 18670706

Group type: EXPERIMENTAL
Intervention: 4.2mg/kg/day of ferrous sulfate + folic acid (50microg)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: 1.4mg/kg/day of ferrous sulfate + folic acid (50microg/day)
Number of subjects: 196

Group type: COMPARATOR
Intervention: 4.2mg/kg/day of ferrous sulfate + folic acid placebo
Number of subjects: 196

Group type: COMPARATOR
Intervention: 1.4mg/kg/day of ferrous sulfate + folic acid placebo
Number of subjects: 196
Study: 15837454

Group type: EXPERIMENTAL
Intervention: Patient intervention (targeted communication about fall and fracture prevention and osteoporosis diagnosis and treatment delivered through mailings)
Number of subjects: 31715

Group type: EXPERIMENTAL
Intervention: Physician intervention (one‐on‐one academic detailing encounters covering fall and fracture prevention and osteoporosis)
Number of subjects: 31715

Group type: EXPERIMENTAL
Intervention: Both patient and physician interventions
Number of subjects: 31715

Group type: COMPARATOR
Intervention: No patient and no physician intervention
Number of subjects: 31715

Group type: EXPERIMENTAL
Intervention: Patient intervention
Number of subjects: 31715
Study: 12544411

Group type: EXPERIMENTAL
Intervention: HAART (highly active antiretroviral therapy)
Number of subjects: 19
Study: 10486394

Group type: EXPERIMENTAL
Intervention: Phenytoin 300 mg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sodium Valproate 1500 mg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both Phenytoin and Sodium Valproate
Number of subjects: 100
Study: 8897531

Group type: EXPERIMENTAL
Intervention: Zinc oxide and eugenol (ZOE)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Calcium hydroxide (Ca(OH)2)
Number of subjects: 38
Study: 1797358

Group type: EXPERIMENTAL
Intervention: 1 mg metaraminol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2 mg metaraminol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 3 mg metaraminol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Metaraminol (all doses)
Number of subjects: 80
Study: 6338760

Group type: EXPERIMENTAL
Intervention: Metoprolol continued until operation (N = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metoprolol discontinued before operation (N = 10)
Number of subjects: 20
Study: 30057090

Group type: EXPERIMENTAL
Intervention: Nurse-led lymphoma survivorship clinic intervention
Number of subjects: 10
Study: 29231297

Group type: EXPERIMENTAL
Intervention: Warm needling therapy applied to acupoints in the neck and lumbus (Fengchi (GB 20), Tianzhu (BL 10), Neck-Bailao (EX-HN 15), Wangu (GB 12), Tianyou (TE 16), Dachangshu (BL 25), Qihaishu (BL 24), Jiaji (EX-B 2) of L5). Treatment given once every two days, three times a week.
Number of subjects: 81

Group type: COMPARATOR
Intervention: Warm needling therapy applied only to acupoints in the neck (same as group A). Treatment given once every two days, three times a week.
Number of subjects: 81
Study: 24973931

Group type: EXPERIMENTAL
Intervention: Barbed running suture
Number of subjects: 411

Group type: COMPARATOR
Intervention: Knotted interrupted suture (Control)
Number of subjects: 411
Study: 23770206

Group type: EXPERIMENTAL
Intervention: Autonomous choice learning condition with food provided
Number of subjects: 3

Group type: COMPARATOR
Intervention: Controlled choice learning condition with food provided
Number of subjects: 3

Group type: COMPARATOR
Intervention: Controlled choice learning condition without food provided
Number of subjects: 3
Study: 19731015

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI >= 30 kg/m2)
Number of subjects: 2887

Group type: COMPARATOR
Intervention: Non-obese patients (BMI < 30 kg/m2)
Number of subjects: 2887
Study: 18781850

Group type: EXPERIMENTAL
Intervention: Fluvastatin (80 mg/day, n = 420)
Number of subjects: 724

Group type: COMPARATOR
Intervention: Placebo (n = 304)
Number of subjects: 724
Study: 16373648

Group type: EXPERIMENTAL
Intervention: B vitamins (2 mg of folate, 25 mg of B6, and 400 microg of B12)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 14760042

Group type: EXPERIMENTAL
Intervention: Structured diabetes shared care
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 183
Study: 10958125

Group type: EXPERIMENTAL
Intervention: Community educational intervention
Number of subjects: 3013

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3013
Study: 9048404

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once daily for 1 month (30 +/‐ 4 days)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo for 1 month (30 +/‐ 4 days)
Number of subjects: 262
Study: 8504499

Group type: EXPERIMENTAL
Intervention: 900 mg aspirin daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: 50 mg aspirin daily
Number of subjects: 27
Study: 3315266

Group type: EXPERIMENTAL
Intervention: Evening administration at 2000 hr
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Evening administration at 2200 hr
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo period
Number of subjects: 30
Study: 30136619

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (5 capsules of fish-oil-derived omega-3, each 1 g containing 180 mg eicosapentaenoic acid and 120 mg docosahexanoic acid)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation
Number of subjects: 54
Study: 26359113

Group type: EXPERIMENTAL
Intervention: Typhoid vaccination
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (placebo) injection
Number of subjects: 24
Study: 24774260

Group type: EXPERIMENTAL
Intervention: Optimized glucose control with insulin (target glucose, 80-120 mg/dL)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional control (target glucose, <180 mg/dL)
Number of subjects: 104
Study: 22660798

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) and TNF-α inhibitors
Number of subjects: 55
Study: 20194522

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18612266

Group type: EXPERIMENTAL
Intervention: Positive words (PW, N=248)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Partially negative words (NW1, N=241)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Totally negative words (NW2, N=247)
Number of subjects: 614

Group type: COMPARATOR
Intervention: No words (NW, N=35)
Number of subjects: 614
Study: 16470437

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg before operation and twice thereafter at 8-hour intervals)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (not receiving tranexamic acid)
Number of subjects: 39
Study: 12433712

Group type: EXPERIMENTAL
Intervention: Highest quartile of serum glucose
Number of subjects: 10786

Group type: EXPERIMENTAL
Intervention: Highest quartile of insulin
Number of subjects: 10786

Group type: EXPERIMENTAL
Intervention: Highest quartile of IGF-I
Number of subjects: 10786

Group type: EXPERIMENTAL
Intervention: Highest quartile of IGFBP-3
Number of subjects: 10786
Study: 10651393

Group type: EXPERIMENTAL
Intervention: Leflunomide (100 mg once daily for 3 days, then 20 mg once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 0
Study: 8944081

Group type: COMPARATOR
Intervention: SPf66 vaccine
Number of subjects: 630

Group type: COMPARATOR
Intervention: Inactivated polio vaccine (IPV)
Number of subjects: 630
Study: 1759005

Group type: EXPERIMENTAL
Intervention: Salbutamol 0.3 mg, tid + Beclomethasone dipropionate 0.2 mg, tid
Number of subjects: 10

Group type: COMPARATOR
Intervention: Salbutamol 0.3 mg, tid + Placebo
Number of subjects: 10
Study: 6130076

Group type: EXPERIMENTAL
Intervention: Buspirone 40 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Methaqualone 300 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Diazepam 20 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31215299

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) treatment (4 cycles of 5-minute ischemia followed by 5-minute reperfusion)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham-device treatment
Number of subjects: 36
Study: 28764777

Group type: EXPERIMENTAL
Intervention: 0.05% betamethasone gel
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 2% lidocaine jelly
Number of subjects: 120

Group type: COMPARATOR
Intervention: Unlubricated endotracheal tube (Control)
Number of subjects: 120
Study: 27647062

Group type: EXPERIMENTAL
Intervention: Web-Based Intervention (WI)
Number of subjects: 1488

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1488
Study: 25797743

Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg po bid for 14 days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib 2 mg po daily for 14 days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dabrafenib therapy
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dabrafenib and trametinib therapy
Number of subjects: 13
Study: 22490614

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine formulae
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine formulae (specifically Jing Fan Bai Du san)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study: 20968018

Group type: EXPERIMENTAL
Intervention: Combined photon‐neutron radiotherapy (CPNT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (photon therapy)
Number of subjects: 33
Study: 17875601

Group type: EXPERIMENTAL
Intervention: 20 mT m(‐1)r.m.s. EMF exposure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10 mT m(‐1)r.m.s. EMF exposure
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0 mT m(‐1)r.m.s. (non-exposed sessions)
Number of subjects: 40
Study: 16043964

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (3 g/day)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Oral valacyclovir (8 g/day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: No prophylaxis (Control group)
Number of subjects: 83